Apimeds Pharmaceuticals US, Inc. Cash Flow Statement

Cash Flow Statement Dec2023 Dec2024
Operating Activities
Net Income -0.78M-1.39M
Share-based Compensation 0.07M
Cash from Operations -0.63M-0.73M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.01M0.08M
Change in Working Capital
Change in Accured Expenses 0.05M0.54M
Other Working Capital Changes 0.01M-0.00M
Financing Activities
Cash from Financing Activities 1.03M0.33M
Additional items
Change in Cash 0.40M-0.41M
Beginning Cash Balance -0.40M0.41M
Free Cash Flow -0.63M-0.73M
Net Cash Flow 0.40M-0.41M